New treatments development in NMIBC

Clinical decision making for non muscle-invasive bladder cancer and new tools for adjuvant treatment for these tumors take a large part of this webinar. Furthermore, in an era of BCG shortage, it is important for urologists to be aware of the latest developments (trials) and of all the drugs currently in the pipeline (systemic drug, intravesical molecule, and combo). Lastly, this session will deal with personalized treatment and its underlying molecular characterization of non muscle bladder cancer.